A research group led by Dr Susan Childress have developed a novel treatment for a variety of immune-mediated diseases. The complement receptors CR1 and CR2 are known to be involved in the induction of B cells under inflammatory conditions that occur in immune-mediated diseases. Through administering an IncRNA sequence that regulates CR1 expression, the induction of B-cells can be directly controlled for the treatment immune-mediated diseases such as cancer, autoimmune disease, and a variety of infections.